Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
BIOCEPT INC (BIOC)
|
Add to portfolio |
|
|
|
| Price: |
$3.84
| | Metrics |
| OS: |
2.63
|
M
| |
|
|
| Market cap: |
$10.1
|
M
| |
|
|
|
Net cash:
|
$6.63
|
M
| |
$2.53
|
per share
|
|
EV:
|
$3.45
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
|
| |
|
|
|
EBIT
|
|
| |
|
|
| EPS |
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 | Dec-31-14 |
| Revenues | 61.2 | 27.5 | 5.5 | 3.3 | 5.1 | 3.2 | 0.6 | 0.1 |
| Revenue growth | 123.0% | 396.7% | 70.1% | -35.9% | 57.3% | 428.5% | 357.2% | -0.6% |
| Cost of goods sold | 37.8 | 21.3 | 11.0 | 10.1 | 9.3 | 6.9 | 4.6 | 2.2 |
| Gross profit | 23.5 | 6.1 | -5.4 | -6.8 | -4.3 | -3.7 | -4.0 | -2.0 |
| Gross margin | 38.3% | 22.3% | -98.6% | -209.3% | -84.4% | -114.7% | -653.6% | -1526.9% |
| Sales and marketing | 8.3 | 6.4 | 5.9 | 5.9 | 6.3 | 5.1 | 3.9 | 2.1 |
| Research and development | 5.0 | 5.2 | 4.7 | 4.5 | 3.4 | 2.7 | 2.9 | 4.5 |
| General and administrative | 12.6 | 10.0 | 7.0 | 7.1 | 7.2 | 6.6 | 5.7 | 5.2 |
| EBIT | -2.4 | -15.5 | -23.1 | -24.3 | -21.2 | -18.0 | -16.4 | -13.9 |
| EBIT margin | -3.9% | -56.3% | -417.1% | -746.4% | -417.8% | -559.2% | -2690.7% | -10399.1% |
| Pre-tax income | -2.7 | -17.8 | -25.1 | -24.6 | -21.6 | -18.4 | -16.9 | -15.9 |
| Income taxes | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | | 0.0% | 0.0% | | | | | |
| Net income | -2.8 | -17.8 | -25.3 | -25.2 | -21.6 | -18.4 | -16.9 | -15.9 |
| Net margin | -4.6% | -64.9% | -456.9% | -775.6% | -426.4% | -570.9% | -2779.0% | -11892.3% |
| |
| Diluted EPS | ($0.19) | ($1.50) | ($12.23) | ($9.01) | ($23.58) | ($1.92) | ($3.07) | ($3.97) |
| Shares outstanding (diluted) | 14.8 | 11.8 | 2.1 | 2.8 | 0.9 | 9.6 | 5.5 | 4.0 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|